cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.3886/e182162
title: Confirmatory Factor Analysis of the Older Adult's Security Perspectives

description: In addition to the United Nation Development Program (UNDP), the survey covers items viewed by three experts in gerotological field interests of older adults' security perspectives. The factor items cover the areas of "Human Security" developed by UNDP, including economic security, health security, personal security, political security, food security, environmental security, and community security. The questionnaries have been divided into two parts: socioeconomic data and 7-items of security. The major objective of the project was to identify the older adults' security perspectives on security in real-world practical settings. SPSS and AMOS programs were used to collect for a model that fit an older adult's security. The survey was administered from June 2021 to March 2022 to a preferred sample of older adults aged 60 or over who had resided in the sampling setting for at least two years. <br>
description: A weight variable (part 1) with 10 variables has been added and is utilized exclusively for sociodemographic data analysis, while the 43 variables of part 2 must be used for exploratory and confirmatory factors analysis.
description: Response Rates: For part 2 (Older Adult's Security Qeustionnarie [OA-SQ]), 487 participants were contacted for the individual survey as a face-to-face survey. Of these contaracts, only one was ineligible to participate becuase participants reported feeling uncomfortable talking with the security during the interview. The responses rate for the survey of part 1 (sociodemographic data) was 95 percent. Response rate for Part 2 (Older Adult's security perspectives) were 98 percent.
description: Presence of Common Scales: Part 2: The basic needs-related health of security tool<br>Instruction: Please choose the items that are your satisfy. <br><br> 1 Not true Incorrect or inaccurate <br> 2 Not sure Feelings of confident certainty<br> 3 True Conforming to reality or fact
description: Using cluster sampling with a confidence level of 95% and an error margin of 5%, the G* power algorithm calculated that at least 380 participants will be recruited from a province in northern Thailand containing 177,944 individuals.
description: Older Thai adults of Thailand living in household. Smallest Geographic Unit: Weight & Hight
description: paper and pencil interview (PAPI); self-enumerated questionnaire;
DOI: 10.3886/e182162v1-167222
title: Confirmatory Factor Analysis of the Older Adult's Security Perspectives

description: In addition to the United Nation Development Program (UNDP), the survey covers items viewed by three experts in gerotological field interests of older adults' security perspectives. The factor items cover the areas of "Human Security" developed by UNDP, including economic security, health security, personal security, political security, food security, environmental security, and community security. The questionnaries have been divided into two parts: socioeconomic data and 7-items of security. The major objective of the project was to identify the older adults' security perspectives on security in real-world practical settings. SPSS and AMOS programs were used to collect for a model that fit an older adult's security. The survey was administered from June 2021 to March 2022 to a preferred sample of older adults aged 60 or over who had resided in the sampling setting for at least two years. <br>
description: A weight variable (part 1) with 10 variables has been added and is utilized exclusively for sociodemographic data analysis, while the 43 variables of part 2 must be used for exploratory and confirmatory factors analysis.
description: Response Rates: For part 2 (Older Adult's Security Qeustionnarie [OA-SQ]), 487 participants were contacted for the individual survey as a face-to-face survey. Of these contaracts, only one was ineligible to participate becuase participants reported feeling uncomfortable talking with the security during the interview. The responses rate for the survey of part 1 (sociodemographic data) was 95 percent. Response rate for Part 2 (Older Adult's security perspectives) were 98 percent.
description: Presence of Common Scales: Part 2: The basic needs-related health of security tool<br>Instruction: Please choose the items that are your satisfy. <br><br> 1 Not true Incorrect or inaccurate <br> 2 Not sure Feelings of confident certainty<br> 3 True Conforming to reality or fact
description: Using cluster sampling with a confidence level of 95% and an error margin of 5%, the G* power algorithm calculated that at least 380 participants will be recruited from a province in northern Thailand containing 177,944 individuals.
description: Older Thai adults of Thailand living in household. Smallest Geographic Unit: Weight & Hight
description: paper and pencil interview (PAPI); self-enumerated questionnaire;
DOI: 10.25550/7c-ck1a
title: Role of the novel ECM protein SNED1 in Knockout of the gene encoding the extracellular matrix protein SNED1 in craniofacial morphogenesis

description: Title: Knockout of the gene encoding the extracellular matrix protein SNED1 results in early neonatal lethality and craniofacial malformations.

Anna Barqué, Kyleen Jan, Emanuel De La Fuente, Christina L Nicholas, Richard O Hynes, Alexandra Naba

Developmental Dynamics, 2021;250(2):274-294.
[https://doi.org/10.1002/dvdy.258](https://doi.org/10.1002/dvdy.258)
PMCID: PMC8721894


Background: The extracellular matrix (ECM) is a fundamental component of multicellular organisms that orchestrates developmental processes and controls cell and tissue organization. We previously identified the novel ECM protein SNED1 as a promoter of breast cancer metastasis and showed that its level of expression negatively correlated with breast cancer patient survival. Here, we sought to identify the roles of SNED1 during murine development.
Results: We generated two novel Sned1 knockout mouse strains and showed that Sned1 is essential since homozygous ablation of the gene led to early neonatal lethality. Phenotypic analysis of the surviving knockout mice revealed a role for SNED1 in the development of craniofacial and skeletal structures since Sned1 knockout resulted in growth defects, nasal cavity occlusion, and craniofacial malformations. Sned1 is widely expressed in embryos, notably by cell populations undergoing epithelial-to-mesenchymal transition, such as the neural crest cells. We further show that mice with a neural-crest-cell-specific deletion of Sned1 survive, but display facial anomalies partly phenocopying the global knockout mice. 
Conclusions: Our results demonstrate requisite roles for SNED1 during development and neonatal survival. Importantly, the deletion of 2q37.3 in humans, a region that includes the SNED1 locus, has been associated with facial dysmorphism and short stature.
DOI: 10.18141/1995730
title: 9A Injection: July 26 thru November 21, 2022

description: Processed Gladwin Tensor Strainmeter, Optical Fiber Tensor Strainmeter, and well pressure data from the well 9A injections from July 26 thru November 21, 2022, at the North Avant Field, OK
DOI: 10.17632/br4db84s2w.1
title: Test

description: TCP SYN Flood pcap to csv
DOI: 10.20350/digitalcsic/17061
title: Anadon et al. Ecosphere - Jamaica Bay datasets [Dataset]

description: Contains five numbered files: 0: Readme file 1: Raw dataset from the seine sampling in Jamaica Bay, as obtained from the annual seine survey of young striped bass (Morone saxatilis) by the New York State Department of Environmental Conservation (NYSDEC). 2. Standardized-by-sampling-effort dataset, and obtained from the raw dataset (1). See main text and supplementary materials for sampling effort and seines per month and year. 3. Species abundance x year matrix for analyses. This is the matrix used for NMDS (untransformed) and all posterior analyses, and obtained from the standardized dataset (2). 4. Environmental data in Jamaica Bay used in this work (i.e. annual values) as obtained from the NYC Water Quality Survey database, collected by the NYC Department of Environmental Protection. See main text for selection of sampling stations and averaging. 5. Species traits dataset used for analyses, with data obtained from www.Fishbase.org and authors´ knowledge (i.e. migrant/resident). All original data employed in this work (i.e. files 1, 4, 5) comes from publicly available datasets. See further information on the main text of the publication and its references.
DOI: 10.17632/hsv63d9vss.1
title: Quantification of the REE3+ aqua ions and chloride species in aqueous fluids by in situ Raman spectroscopy using perturbations of the water band

description: Here we develop a new method using the water vibrational mode which is modified by the addition of REE3+ ions and REE chloride species. The Raman spectra for the vibrational band of water (2700 to 3900 cm-1) were collected at 25 ºC in aqueous solutions buffered at pH 2 with variable NaCl (0.2 to 3.2 m), NdCl3 and YbCl3 (0.1 to 0.6 m) concentrations. The water vibrational band can be fitted by three Gaussian sub-peaks, which were further quantified using a multivariate curve resolution analysis. The water band was de-convoluted into individual spectra representing bulk H2O and the perturbations of the water band caused by the addition of Cl-, REE3+, and REE chloride species (REECln3-n). The multivariate analysis indicates that water molecules in the REE3+ ions hydration shell perturbed by Cl- ions result in an asymmetric Raman peak at 3430 cm-1 with a shoulder at 3320 cm-1. Quantification of REE speciation based upon these perturbations of the water band indicates that the REE3+ aqua ion dominates in acidic solutions at 25 ºC, and the REE chloride species (REECl2+, REECl2+, and REEClin3-n·Clom- ) can make up to 20 mol% in Cl-rich solutions (&gt;3m Cltotal).
DOI: 10.17632/d4f7g8hs5z.1
title: C4d DSA Dataset 11/2010 - 4/2023

description: Background:

C4d immunostaining of surveillance endomyocardial biopsies (EMB) and testing for donor specific antibodies (DSA) are routinely performed in the first year of heart transplantation (HTx) in adult patients. C4d immunostaining and DSA positivity have not been evaluated together with respect to clinical outcomes in the contemporary era (2010–current).

Methods:

This was a single center, retrospective study of consecutive EMBs performed between November 2010 and April 2023. The primary objective was to determine whether history of C4d immunostaining and/or DSA positivity could predict death, cardiac death, or retransplant. Secondary analyses included cardiac allograft dysfunction and cardiac allograft vasculopathy. Cox proportional hazards models were used for single predictor and multipredictor analyses.

Results:

A total of 6,033 EMBs from 519 HTx patients were reviewed for the study. There was no significant difference (p = 0.110) in all-cause mortality or cardiac retransplant between four groups: C4d+/DSA+, C4d+/DSA-, C4d-/DSA+, and C4d-/DSA-. The risk for cardiac mortality or retransplant was significantly higher in C4d+/DSA+ versus C4d-/DSA- patients (HR = 4.73; pc = 0.042) but not significantly different in C4d+/DSA- versus C4d-/DSA- patients (pc = 1.000). Similarly, the risk for cardiac allograft dysfunction was significantly higher in C4d+/DSA+ versus C4d-/DSA- patients (HR 3.26; pc = 0.001) but not significantly different in C4d+/DSA- versus C4d-/DSA- patients (pc = 1.000). Accounting for nonadherence, C4d/DSA status continued to predict cardiac allograft dysfunction but no longer predicted cardiac death or retransplant.

Conclusions: 

Medically adherent C4d+/DSA+ HTx patients show significantly greater risk for cardiac allograft dysfunction but not cardiac mortality or retransplant. In contrast, C4d+/DSA- patients represent a new immunopathologic group with a clinical course similar to that of HTx patients without antibody mediated rejection.
DOI: 10.17632/d4f7g8hs5z.2
title: C4d DSA Dataset 11/2010 - 2/2023

description: Background:

C4d immunostaining of surveillance endomyocardial biopsies (EMB) and testing for donor specific antibodies (DSA) are routinely performed in the first year of heart transplantation (HTx) in adult patients. C4d immunostaining and DSA positivity have not been evaluated together with respect to clinical outcomes in the contemporary era (2010–current).

Methods:

This was a single center, retrospective study of consecutive EMBs performed between November 2010 and April 2023. The primary objective was to determine whether history of C4d immunostaining and/or DSA positivity could predict death, cardiac death, or retransplant. Secondary analyses included cardiac allograft dysfunction and cardiac allograft vasculopathy. Cox proportional hazards models were used for single predictor and multipredictor analyses.

Results:

A total of 6,033 EMBs from 519 HTx patients were reviewed for the study. There was no significant difference (p = 0.110) in all-cause mortality or cardiac retransplant between four groups: C4d+/DSA+, C4d+/DSA-, C4d-/DSA+, and C4d-/DSA-. The risk for cardiac mortality or retransplant was significantly higher in C4d+/DSA+ versus C4d-/DSA- patients (HR = 4.73; pc = 0.042) but not significantly different in C4d+/DSA- versus C4d-/DSA- patients (pc = 1.000). Similarly, the risk for cardiac allograft dysfunction was significantly higher in C4d+/DSA+ versus C4d-/DSA- patients (HR 3.26; pc = 0.001) but not significantly different in C4d+/DSA- versus C4d-/DSA- patients (pc = 1.000). Accounting for nonadherence, C4d/DSA status continued to predict cardiac allograft dysfunction but no longer predicted cardiac death or retransplant.

Conclusions: 

Medically adherent C4d+/DSA+ HTx patients show significantly greater risk for cardiac allograft dysfunction but not cardiac mortality or retransplant. In contrast, C4d+/DSA- patients represent a new immunopathologic group with a clinical course similar to that of HTx patients without antibody mediated rejection.
DOI: 10.17632/d4f7g8hs5z.3
title: pAMR DSA Dataset 11/2010 - 2/2023

description: Background: Surveillance donor-specific antibody (DSA) and pathologic antibody-mediated rejection (pAMR) testing is recommended in the first year after heart transplantation (HTx) in adult patients. Whether pAMR testing adds prognostic information to contemporary DSA testing has not been fully studied.

Methods: This was a single-center study of consecutive endomyocardial biopsies (EMB) performed between November 2010 and February 2023 in adult HTx patients. The primary objective was to evaluate whether pAMR testing contributes additional information to DSA testing to better predict overall survival. Secondary end-points included cardiac survival and allograft dysfunction.

Results: A total of 6,033 EMBs from 544 HTx patients were reviewed for the study. The pAMR+/DSA+ patients had significantly lower overall (pc = 0.013) and cardiac survival (pc = 0.002), while the pAMR+/DSA- and pAMR-/DSA+ patients showed no difference in either outcome compared to the pAMR-/DSA- group. We found significantly lower overall survival in pAMR+/DSA+ patients with allograft dysfunction (pc &lt; 0.001) but not in pAMR+/DSA+ patients without allograft dysfunction (pc = 0.569), when compared to the pAMR-/DSA- without allograft dysfunction group. The pAMR+/DSA+ patients with cardiac allograft dysfunction accounted for 18% of deaths or cardiac retransplants while only representing 4% of the HTx cohort. Moderate or severe primary graft dysfunction (PGD) also was a novel risk factor for the development of de novo DSAs (dnDSA) by 4 weeks post-HTx (p = 0.025).

Conclusions: Surveillance DSA testing may effectively identify high-risk pAMR+ patients. Earlier DSA testing at 10 to 14 days post-HTx should also be considered in moderate or severe PGD patients.
DOI: 10.17632/hjf857dzsy.1
title: Age and composition of garnet bearing SCLM xenoliths

description: Lu-Hf isotope data, major element and REE data for garnet bearing peridotites and pyroxenites from SCLM
DOI: 10.17632/hjf857dzsy.2
title: Composition of garnet bearing SCLM xenoliths

description: Major element and REE data for garnet bearing peridotites and pyroxenites from SCLM
DOI: 10.17632/j5xdt8fd3s.1
title: Investigação clínica com microdoses de canabinóides para tratamento da Doença de Alzheimer

description: Alzheimer's disease (AD) is closely linked to the accumulation of neurotoxins derived from Aβ and tau, as well as cognitive impairment. The premise of this project is that the imbalance in the endocannabinoid system occurs in an AD-dependent manner. The connection between dementia, inflammation, Aβ, and changes in the cannabinoid system in experimental AD models has been reported. Cannabinoid microdoses may restore baseline brain function while avoiding major side effects. Despite extensive research on new AD therapies, no significant improvement has been achieved recently, and there is virtually no consensus on how scientists will innovate to shed light on a new treatment. Currently, there are no published studies examining the effect of microdoses on human AD pathology. Cannabinoid-based therapy has emerged as crucial for treating many diseases considered incurable. The expected results of this project will provide important information on the ability of cannabinoid microdoses to offset neurochemical imbalances during AD progression, thus improving memory performance, as well as how they may affect inflammation, Aβ levels, and tau. The key point is to provide evidence that cannabinoid microdoses can serve as an effective treatment for AD while avoiding major side effects. The goal of this project is to determine the effect of cannabinoid microdoses in AD patients, with the aim of evaluating memory and cognition, assessing cerebral blood perfusion, and verifying proteins relevant to inflammation and progression associated with AD. The results are expected to establish that cannabinoid microdoses are essential to restore the baseline function of the endocannabinoid system in AD-affected brains and their beneficial effects. This project may be instrumental in validating new therapeutic approaches for AD.
DOI: 10.17632/j5xdt8fd3s.2
title: Investigação clínica com microdoses de canabinóides para tratamento da Doença de Alzheimer

description: Alzheimer's disease (AD) is closely linked to the accumulation of neurotoxins derived from Aβ and tau, as well as cognitive impairment. The premise of this project is that the imbalance in the endocannabinoid system occurs in an AD-dependent manner. The connection between dementia, inflammation, Aβ, and changes in the cannabinoid system in experimental AD models has been reported. Cannabinoid microdoses may restore baseline brain function while avoiding major side effects. Despite extensive research on new AD therapies, no significant improvement has been achieved recently, and there is virtually no consensus on how scientists will innovate to shed light on a new treatment. Currently, there are no published studies examining the effect of microdoses on human AD pathology. Cannabinoid-based therapy has emerged as crucial for treating many diseases considered incurable. The expected results of this project will provide important information on the ability of cannabinoid microdoses to offset neurochemical imbalances during AD progression, thus improving memory performance, as well as how they may affect inflammation, Aβ levels, and tau. The key point is to provide evidence that cannabinoid microdoses can serve as an effective treatment for AD while avoiding major side effects. The goal of this project is to determine the effect of cannabinoid microdoses in AD patients, with the aim of evaluating memory and cognition, assessing cerebral blood perfusion, and verifying proteins relevant to inflammation and progression associated with AD. The results are expected to establish that cannabinoid microdoses are essential to restore the baseline function of the endocannabinoid system in AD-affected brains and their beneficial effects. This project may be instrumental in validating new therapeutic approaches for AD.
DOI: 10.17632/j5xdt8fd3s.3
title: Clinical research with microdoses of cannabinoids for the treatment of Alzheimer's Disease

description: Alzheimer's disease (AD) is closely linked to the accumulation of neurotoxins derived from Aβ and tau, as well as cognitive impairment. The premise of this project is that the imbalance in the endocannabinoid system occurs in an AD-dependent manner. The connection between dementia, inflammation, Aβ, and changes in the cannabinoid system in experimental AD models has been reported. Cannabinoid microdoses may restore baseline brain function while avoiding major side effects. Despite extensive research on new AD therapies, no significant improvement has been achieved recently, and there is virtually no consensus on how scientists will innovate to shed light on a new treatment. Currently, there are no published studies examining the effect of microdoses on human AD pathology. Cannabinoid-based therapy has emerged as crucial for treating many diseases considered incurable. The expected results of this project will provide important information on the ability of cannabinoid microdoses to offset neurochemical imbalances during AD progression, thus improving memory performance, as well as how they may affect inflammation, Aβ levels, and tau. The key point is to provide evidence that cannabinoid microdoses can serve as an effective treatment for AD while avoiding major side effects. The goal of this project is to determine the effect of cannabinoid microdoses in AD patients, with the aim of evaluating memory and cognition, assessing cerebral blood perfusion, and verifying proteins relevant to inflammation and progression associated with AD. The results are expected to establish that cannabinoid microdoses are essential to restore the baseline function of the endocannabinoid system in AD-affected brains and their beneficial effects. This project may be instrumental in validating new therapeutic approaches for AD.
DOI: 10.17632/j5xdt8fd3s.4
title: A RANDOMIZED CLINICAL TRIAL OF LOW-DOSE CANNABIS EXTRACT IN ALZHEIMER’S DISEASE

description: Alzheimer's disease (AD) is closely linked to the accumulation of neurotoxins derived from Aβ and tau, as well as cognitive impairment. The premise of this project is that the imbalance in the endocannabinoid system occurs in an AD-dependent manner. The connection between dementia, inflammation, Aβ, and changes in the cannabinoid system in experimental AD models has been reported. Cannabinoid microdoses may restore baseline brain function while avoiding major side effects. Despite extensive research on new AD therapies, no significant improvement has been achieved recently, and there is virtually no consensus on how scientists will innovate to shed light on a new treatment. Currently, there are no published studies examining the effect of microdoses on human AD pathology. Cannabinoid-based therapy has emerged as crucial for treating many diseases considered incurable. The expected results of this project will provide important information on the ability of cannabinoid microdoses to offset neurochemical imbalances during AD progression, thus improving memory performance, as well as how they may affect inflammation, Aβ levels, and tau. The key point is to provide evidence that cannabinoid microdoses can serve as an effective treatment for AD while avoiding major side effects. The goal of this project is to determine the effect of cannabinoid microdoses in AD patients, with the aim of evaluating memory and cognition, assessing cerebral blood perfusion, and verifying proteins relevant to inflammation and progression associated with AD. The results are expected to establish that cannabinoid microdoses are essential to restore the baseline function of the endocannabinoid system in AD-affected brains and their beneficial effects. This project may be instrumental in validating new therapeutic approaches for AD.